This article was originally published in The Gray Sheet
Executive SummaryCiba Corning Diagnostics gains rights to use Metra Biosystems' pyridinium crosslinks technology to develop a diagnostic test for bone resorption for its fully automated ACS: 180(R) system. CCD will commercialize the test internationally except in Japan, and will pay "upfront licensing fees and ongoing royalties," Metra says. In December, the Palo Alto, California-based firm negotiated a deal under which Lilly subsidiary Hybritech will develop a pyridinium crosslinks-based laboratory test. Metra's Pyrilinks bone resorption test is "under review at FDA"
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.